APYX REMINDER: Hagens Berman Reminds Apyx Medical Corporation (APYX) Investors of Lead Plaintiff Deadline, Encourages Investors to Contact the Firm

World News: . []

SAN FRANCISCO, May 29, 2019 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP, with nine offices in eight cities around the country and eighty attorneys, reminds investors in Apyx Medical Corporation () of the in the securities class action, No. 8:19-cv-00919, filed in the United States District Court for the Middle District of Florida.

If you purchased or otherwise acquired Apyx Medical securities (the “Class Period”) and suffered significant losses, you may qualify to be a lead plaintiff – one who selects and oversees the attorneys prosecuting the case.

If you wish to serve as a lead plaintiff in this class action, you must move the Court no later than .  Contact Hagens Berman immediately for more information about the case and being a lead plaintiff:

or contact Reed Kathrein, who is leading the firm’s investigation, by calling or emailing

According to the complaint, Defendants misstated and/or concealed that (1) Apyx’s J-Plasma clinical study for dermal resurfacing did not meet its primary efficacy endpoint, and (2) the study did not support the Company’s application to obtain regulators’ approval for such use.

“We’re focused on investors’ losses, certain matters flagged in a recent bearish analyst report, and whether investors may have been misled,” said Hagens Berman partner Reed Kathrein.

More news and information about Hagens Berman Sobol Shapiro LLP

Published By:

Globe Newswire: 01:08 GMT Thursday 30th May 2019

Published: .

Search for other references to "apyx" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us